Real-World Effectiveness and Safety of Upadacitinib in Crohn&apos;s disease: A Multi-Centre Study

Inflammatory Bowel Disease

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

J Crohns Colitis

D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S

doi: 10.1093/ecco-jcc/jjaf080

Inflammatory Bowel Disease

The Effectiveness of second-and-third line biologics in perianal Crohn's disease - a multicenter propensity score-matched study

J Crohns Colitis

Shani U, State M, Mateescu RB, Davidoiu AM, Negreanu L, Silva I, Magro F, Lees CW, Plevris N, Roblin X, Castellet-Farrús S, Gonzalez Lama Y, Wang S, Abad C, Imperatore N, Lukas M, Vojtechova G, Ukashi O, Ben-Horin S, Nancey S, Savarino E, Stawczyk-Eder K, Eder P, Toskas A, Kamperidis N, Arebi N, Farkas B, Farkas K, Pipek B, Falt P, Karmiris K, Nikolaou P, Krznaric Z, Brinar M, Hoentjen F, van Lierop L, Barreiro-de Acosta M, Zaborowska M, Zagorowicz E, Pugliese D, Cuccia G, Truyens M, Kopylov U

doi: 10.1093/ecco-jcc/jjaf099

Inflammatory Bowel Disease

Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn's Disease Patients

Inflamm Bowel Dis

Gebeyehu GG, Broglio G, Liu E, Limdi JK, Selinger C, Fiske J, Razanskaite V, Smith PJ, Flanagan PK, Subramanian S

doi: 10.1093/ibd/izae174

Inflammatory Bowel Disease

Efficacy of Ustekinumab and Vedolizumab Among Postoperative Crohn's Disease Patients as Postoperative Prophylaxis and Rescue Therapy: Real-world Data

Inflamm Bowel Dis

Ertem FU, Rivers CR, Ghaffari AA, Watson AR, Tang G, Schwartz M, Johnston E, Barrie A, Harrison J, Dueker JM, Hartman D, Binion DG

doi: 10.1093/ibd/izae137

Inflammatory Bowel Disease

Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naïve Patients with Crohn's Disease and Fistula Initiated on Ustekinumab

Adv Ther

Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Lefebvre P, Kerner C, Pilon D

doi: 10.1007/s12325-024-02963-1

Inflammatory Bowel Disease

Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 GRAVITI Study

Gastroenterology

Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q, Ritter T, Seidler U, Olurinde M, Vetter ML, Yee J, Yang Z, Wang Y, Johanns J, Han C, Sahoo A, Terry NA, Sands BE, D'Haens G

doi: 10.1053/j.gastro.2025.02.033

Inflammatory Bowel Disease

Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials

Clin Gastroenterol Hepatol

Colombel JF, Lacerda AP, Irving PM, Panaccione R, Reinisch W, Rieder F, Steinlauf A, Schwartz D, Feng T, Dubcenco E, Anyanwu SI, Laroux FS, Cunneen C, Powell N

doi: 10.1016/j.cgh.2024.08.032

Inflammatory Bowel Disease

Gaps between European Crohn's Colitis Organisation quality standards of care and the real world on structure of IBD units across Europe: results from E-QUALITY survey

J Crohns Colitis

Fiorino G, Walsh A, Adamina M, Barreiro-Acosta M, Ali MP, Bortlik M, Burisch J, Dignass A, Drobne D, Faiz O, Ferrante M, Fierens L, Godny L, Gojdicova A, Iacucci M, Jӓghult S, Karmiris K, Kirchgesner J, Restellini S, Rosini F, Shouval D, Van Deen W, Yanai H, Zagórowicz E, Fidalgo C, European Crohn’s Colitis Organisation

doi: 10.1093/ecco-jcc/jjaf094

Inflammatory Bowel Disease

Long-Term Outcome of Colonic and Ileal Crohn's Disease: A Two-Decade Population-Based Study in Pediatric-Onset Disease

Inflamm Bowel Dis

Fumery M, Savoye G, Sarter H, Dupont-Lucas C, Bertrand V, Wils P, Richard N, Guillon N, Gower-Rousseau C, Turck D, Ley D, Leroyer A, EPIMAD group

doi: 10.1093/ibd/izaf133

Related content

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

The Effectiveness of second-and-third line biologics in perianal Crohn's disease - a multicenter propensity score-matched study

Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn's Disease Patients

Efficacy of Ustekinumab and Vedolizumab Among Postoperative Crohn's Disease Patients as Postoperative Prophylaxis and Rescue Therapy: Real-world Data

Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naïve Patients with Crohn's Disease and Fistula Initiated on Ustekinumab

Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 GRAVITI Study

Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials

Gaps between European Crohn's Colitis Organisation quality standards of care and the real world on structure of IBD units across Europe: results from E-QUALITY survey

Long-Term Outcome of Colonic and Ileal Crohn's Disease: A Two-Decade Population-Based Study in Pediatric-Onset Disease